Eli Lilly Raises Sales Outlook on Zepbound and Mounjaro Surge
Eli Lilly lifted its full-year sales forecast after obesity and diabetes drug sales climbed sharply in Q3, with the CEO citing room for dramatic market growth.
Eli Lilly raised its annual sales outlook after recording another quarter of surging demand for its blockbuster weight-loss injection Zepbound and diabetes therapy Mounjaro, the pharmaceutical giant reported.
The Indianapolis-based drugmaker's chief executive signaled confidence that the obesity treatment market has substantial room to expand, describing the potential as "dramatic" — a characterization that underscores how central GLP-1 class drugs have become to the company's long-term growth strategy.
Read more Reddit Stock Falls After Weak Guidance and Login Wall Plans →
The back-to-back quarterly gains for both Zepbound and Mounjaro reflect accelerating consumer and physician uptake of the medications, which belong to a class of drugs that have reshaped the weight-management and metabolic disease landscape in a relatively short period. Analysts have increasingly viewed Lilly as one of the primary beneficiaries of that structural shift in healthcare spending.
Raising a sales forecast amid strong drug performance is a routine corporate signal, but the CEO's language around "dramatic" expansion points to a longer-horizon thesis: that current prescription volumes represent only an early slice of the addressable patient population for obesity and related conditions. Supply constraints and insurance coverage gaps have previously limited access, factors the company has been working to address.
The updated guidance reflects management's expectation that momentum will continue into the final quarter of the year, even as competitors pursue their own entries in the GLP-1 space. Continue reading at US Top News and Analysis.
